Akers Biosciences Co-Founder and Executive Chairman to Assume Duties of President & CEO
March 12 2014 - 1:15PM
Akers Biosciences, Inc. (LSE:AKR) (Nasdaq:AKER), (the "Company" or
"ABI"), a leading designer and manufacturer of rapid diagnostic
screening and testing products, today announces that President and
CEO Thomas A. Nicolette will be stepping down from the board and
leaving the Company, effective March 28, 2014. Mr. Nicolette is the
principal of Nicolette Consulting Group Limited, a business
management consulting firm specializing in capital raising and
financial planning. Through a series of consulting agreements, Mr.
Nicolette has held the position of ABI's President since February
2007 and Chief Executive Officer since April 2008. Most recently,
he played an integral role in ABI's successful listing on the
NASDAQ Capital Market raising $15 million to support ABI's growth.
Raymond F. Akers, Jr. PhD, the Company's Co-founder and Executive
Chairman of the Board will assume the duties of President and CEO
effective March 28, 2014; Mr. Nicolette will assist in the
transition.
Dr. Akers stated, "On behalf of Akers Biosciences, my fellow
Board Members and our employees, I want to thank Mr. Nicolette for
his tireless efforts on our behalf over the last seven years,
especially as it relates to achieving the financial stability that
now enables the Company to entirely focus on the execution of its
business plan. We wish Tom much success in his future
endeavors."
Dr. Akers continued, "With the benefit of our fully-subscribed
NASDAQ IPO in January of this year, Akers Biosciences is
well-positioned to move to its next phase of operational strategy
focused on rapid commercialization of existing and near-term
products, as well as new product development. We have a
well-defined business plan in place for immediate execution, and we
have begun a comprehensive search for proven leaders in medical
device discovery and commercial development to achieve our staffing
goals."
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid,
point of care screening and testing products designed to bring
healthcare information both rapidly and directly to the consumer or
healthcare provider. The Company has advanced the science of
diagnostics while responding to major shifts in healthcare through
the development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical products distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics. Additional
information on the Company and its products can be found at
www.akersbiosciences.com.
Cautionary Statement Regarding Forward Looking
Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
CONTACT: For more information:
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Akers Biosciences, Inc.
Tel. +1 856 848 8698
Jon Cunningham
RedChip Companies, Inc.
Tel. +1 407 644 4256 x107
Antony Legge / James Thomas
Daniel Stewart (Nomad and Broker)
Tel. +44 (0)20 7776 6550
Ben Simons
Vigo Communications
Tel. +44 (0)20 7016 9574
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jul 2023 to Jul 2024